Still other reports demonstrated that expression of hepatic CYP7B1 was reduced in NAFLD, early NASH, and T2DM, but NASH with fibrosis may lead to an upregulation of the alternative BA pathway caused by activated CYP7B1 expression [81,82]. This evidence concerns the gene CYP7B1 and metabolic dysfunction-associated steatotic liver disease.